Company Profile
Trevi Therapeutics Stock Price, News & Catalysts
- Ticker:
- TRVI
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
18.08 USD (+0.67%)
Close
Last updated: August 24, 2026
1.92B USD
Market cap
Why the stock is moving
As of Aug 24, 2026, TRVI closed up 0.67% at $18.08. No new same-company headline was identified in the current news window.
Company overview
Business overview
Trevi Therapeutics is a neuroscience and cough-related company focused on chronic cough and severe pruritus biology. Its programs aim to address symptom burdens with targeted therapies.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Trevi sits in specialty biotechnology.
Business Model Characteristics
The company depends on clinical validation, symptom-specific differentiation, and the ability to build a focused CNS/respiratory story.
Position Within the Biotechnology Landscape
Trevi is a high-catalyst specialty name where clinical data can quickly reshape the investment case.
Future catalysts
- Trevi’s catalysts are Haduvio and the chronic-cough / pruritus opportunities, with the next clinical step deciding whether the asset can become a real franchise. The stock is still driven by proof that the mechanism works in patients.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Trevi Therapeutics (TRVI)?
Trevi Therapeutics (TRVI) most recently closed at 18.08 USD, a +0.67% move versus the previous session.
What is the market cap of Trevi Therapeutics (TRVI)?
Trevi Therapeutics currently has a market capitalization of 1.92B USD on BioPharmSignal.
What does Trevi Therapeutics do?
Trevi Therapeutics is a neuroscience and cough-related company focused on chronic cough and severe pruritus biology. Its programs aim to address symptom burdens with targeted therapies.
On which exchange is TRVI stock listed?
Trevi Therapeutics (TRVI) is associated with NASDAQ, United States, Biopharma.
What is Trevi?
Trevi’s catalysts are Haduvio and the chronic-cough / pruritus opportunities, with the next clinical step deciding whether the asset can become a real franchise.
Which conditions is Trevi Therapeutics targeting with Trevi?
Trevi Therapeutics is associated with neuroscience based on its company overview and current catalyst commentary.
How does Trevi Therapeutics describe recent progress with Trevi?
Trevi’s catalysts are Haduvio and the chronic-cough / pruritus opportunities, with the next clinical step deciding whether the asset can become a real franchise.
What is Therapeutics?
Trevi Therapeutics is a neuroscience and cough-related company focused on chronic cough and severe pruritus biology.